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RESUMO
A combinação da quimioterapia e da radio-
terapia revelou-se a terapêutica corrente no car-
cinoma pulmonar não de pequenas células irres-
secável, após a aplicação da radioterapia isolada,
durante vários anos, ter revelado sobrevidas
ABSTRACT
Combined chemotherapy and radiotherapy
has shown to be the correct treatment of
unresectable non-small cell lung cancer, aier many
years of poor survival figures with standard ra-
diotherapy alone. It has also been demonstrated
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pobres. Constatou-se que o benefício da quimio-
terapia se deveu aos esquemas  com cisplatina.
Os autores apresentam os resultados de um
estudo retrospectivo de 100 doentes com carci-
noma pulmonar não de pequenas células, estádio
III, tratados com um esquema sequencial de
quimioterapia e radioterapia, em que avaliam as
sobrevidas média e global, os tempos livres até à
progressão local e à progressão à distância,
constatando que os seus resultados são muito
semelhantes aos publicados na literatura.
REV PORT PNEUMOL 2003; IX (3): 215-223
Palavras-chave: Carcinoma pulmonar não de pequenas
células; quimioterapia e radioterapia sequencial.
that the benefit of chemotherapy is mainly
achieved if cisplatin-based schedules are used. The
authors present a retrospective study of 100 cases
of stage III non-small cell lung cancer treated with
a sequential approach of chemotherapy and ra-
diotherapy and evaluate median and overall sur-
vival, local progression-free survival and distant
progression-free survival.
The results of our series are quite similar to
those published in literature.
REV PORT PNEUMOL 2003; IX (3): 215-223
Key-words: non-small cell lung cancer; sequential
chemo-radiation
INTRODUCTION
Non-small cell lung cancer (NSCLC), ac-
counts for about 80% of all lung cancers and
surgery is the curative treatment33, with 5 year
survival rates of 55%, 30% and 18% in stages I, II
and III, respectively13. Unfortunately, surgery is
only possible in 15% to 25% of cases, due to
loco-regional invasion or disseminated disease
at the diagnosis, or medically inoperable patients
or surgery refusal3,8,41. In locally advanced tu-
mours, those with small and ipsilateral medi-
astinal lymph nodes — minimal N2 — are a thera-
peutic challenge, because they may benefit with
neo-adjuvant treatment3,32. Randomized studies
published in 1994 have confirmed that be-
nefit25,26 and the studies from Memorial Sloan-
Kettering Cancer Center22 and from Southwest
Oncology Group1 have demonstrated resection
rates of 65% and 73%, respectively, after chemo-
therapy (CT) and radiotherapy (RT). All other
stage IIIA and all stage IIIB cases are classi-
cally considered unresectable18,24 and, since many
years, RT alone has been the standard therapy19.
Although the results were extremely disappoin-
ting, with median survival less than one year
and 5 year survival rates of 0% to 9%6,10,15,17,32,
it was the only chance of cure for a very small
number of patients.
From the end of 80 decade and beginning
of 90 decade, some authors have shown that
the ideal approach in unresectable NSCLC is
combining CT and RT, in patients with good
performance status and minimal weight loss
2,4,5,8,11,12,16,17,21,23.28.29,35,39. In most series. this com-
bination demonstrated a survival gain of 2 to 4
months and two times more survivors at 2 and 3
years with CT schedules containing cispla-
tin18,if combined with RT , when compared with
RT alone20. The randomized study from CALGB,
published in 199011 and up-dated in 199612 with 155
patients presents a median survival gain from
9.7 months to 13.8 months and a 3 year sur-
vival from 11% to 23%. Other randomized study
from Institut Gustave Roussy21, with 353 patients,
shows a median survival gain from 10 months to
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12 months and a 3 year survival from 5% to
11%. Both an Italian group8 and a Spanish group34,
with 66 and 45 patients, respectively, have shown
encouraging results with combined CT-RT.
However, timing of both modalities is still
controversial, taking in consideration the final
endpoint of a longer survival without increa-
sing the toxicity. With the purpose of clearing
this point, some publications have tried to de-
monstrate the superiority of concurrent CT-RT,
with encouraging results7,9,14,31,36,37,38.40.
MATERIAL AND METHODS
From January 1992 until December 1998, one
hundred patients with stage III NSCLC and
Karnofsky index ≥ 70, have been treated with 3
or 4 cycles of CT followed by RT with 60 Gy/6
weeks. Median age is 64.5 years (range 38-77
years), 90 patients are male and 10 are female.
According to histologic type, 46% are squamous
cell carcinomas. 34% adenocarcinomas. 3%
mixed adenosquamous tumours, 1% large cell
carcinoma and 16% unclassified NSCLC. Ac-
cording to stage, 24% are in stage IIIA and 76%
in stage IIIB. In 23% of the patients, CT sche-
dule includes mitomycin, vindesine and cisplatin
(MVP), in 58% vindesine is changed to ifos-
famide (MIP), in 14% vinorelbine is included in
the schedule combined with ifosfamide and
cisplatin (NIP) and in 5% gemcitabine is asso-
ciated to cisplatin (GP). Complete CT schedule
is presented in Table I. 60% of the patients have













Vinorelbine 30 mg/m2  D1, D8
Ifosfamide 3 mg/m2  D1
Cisplatin 80 mg/m2  D1
Gemcitabine 1000 mg/m2  D1, D8, D15






Patients and treatment features
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courses. Concerning RT, 8% of the patients did
not complete 60Gy, due to disease progression
or poor general condition. The patients and treat-
ments features are summarized in Table II.
Kaplan-Meier method has been used for sur-
vival curves and log rank for significance tests.
RESULTS
Median survival is 17 months. There is not
any statistically significant difference according
to histology: 17 months in squamous cell carci-
nomas and 14 months in adenocarcinomas, with
p= 0.6 (Fig. 1); there is not any statistic diffe-
rence too between stages: 23 months in stage IIIA
and 16 months in stage IIIB, with p= 0.16
(Fig.2); also according to CT schedule and
number of courses, there is not any difference:
18 months with MVP 17 months with MIP, 15
months with NIP and 10 months with GP, with
p= 0.79 (Fig. 3), 16 months with 3 courses and
17 months with 4 courses with p = 0.88 (Fig. 4);
despite the very small number of patients
treated with < 60 Gy, there is almost statisti-
cally significant difference between RT dosis:
17 months with 60 Gy and 9 months with < 60 Gy,
with p= 0.069 (Fig. 5).
Overall survival at 1, 2 and 3 years and sur-
vival probability at 5 years is 69.2%, 36%, 23.3%
and 11.6%, respectively (Fig. 6). Median time
to local progression is 15 months. Local pro-
gression-free survival at 1, 2 and 3 years is
65.9%. 28.7% and 26.7%, respectively (Fig. 7).
Median time to distant progression is 17
months. Distant progression-free survival at 1,2
and 3 years is 58.8%, 38.2% and 34.2%, respec-
tively (Fig. 8). The most frequent first site of dis-
semination is brain in 37% of the cases, followed
by bone (33.3%), lung (16.6%) and liver (13%).
Five patients developed second neoplasic di-
seases: thyroid, pancreas, prostate, myelodisplasia
and rectum.
Fig. 1 — Survival curve according to histology
Fig. 2 — Survival curve according to stage
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Fig. 3 — Survival curve according to CT schedule Fig. 4 — Survival curve according to number of CT courses
Fig. 5 — Survival curve according to RT dosis Fig. 6 — Overall survival
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DISCUSSION
Today, combination of CT and RT is the
standard treatment of unresectable NSCLC.
Concerning CT, it has been demonstrated that
cisplatin is the reference to combine with other
drugs18. The sequential approach of CT and RT
has been largely performed, showing an im-
provement of survival compared with RT
alone2,4,5,11,12,17,20,21.29,35.39.
TABLE III
Results overview in  differents series
* Randomized studies
Fig. 7 — Local progression-free survival Fig. 8 — Distant progression-free survival
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Our series of 100 patients has 76% of cases
with stage IIIB and a slight predominance of
squamous cell carcinomas. CT consisted of 3 or
4 courses and two of the so-called new drugs —
vinorelbine and gemcitabine — were introduced
in our schedule in 1996 and 1997, respectively,
leading to a smaller number of patients treated
with those drugs. However, at this time, there is
not any difference in survival results according
to the CT scheme. Histologic type did not show
either any prognostic relevance. The statistic dif-
ference between RT dosis, almost significant,
probably means that 60 Gy might be the mini-
mal dosis required in NSCLC, which perhaps
means that dosis has prognostic value, as it is
suggested in a recent recursive partitioning analy-
sis30.
The results of our series are quite similar to
those published in literature with combined
CT-RT in NSCLC (Table III) with 2- and 5-year
survival rates of 36% and 11,6%, respectively.
Nevertheless, better results could be achieved
with improvements in both therapeutic modali-
ties. Concerning CT a wider utilization of the new
drugs seems to obtain promising results with more
responses and longer survival, and this fact is
more attractive if RT is given concurren-
tly9,14,36,37,38,40, in spite of more toxicity, mainly
esophageal. What concerns RT, a sequential
approach of CT-RT. in which part of RT was
given with accelerated fractionation, obtained a
3-year survival rate of 26%35, bringing to dis-
cussion the benefit of altered fractionation
schemes. On the other hand, 3-dimensional
planning and conformal RT have launched the
debate about the optimal field size (is unin-
volved elective areas irradiation needed?) and
consequent escalation dosis, in order to reach
better local control.
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